0001062993-18-003586.txt : 20180830 0001062993-18-003586.hdr.sgml : 20180830 20180830093119 ACCESSION NUMBER: 0001062993-18-003586 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20180830 FILED AS OF DATE: 20180830 DATE AS OF CHANGE: 20180830 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Trillium Therapeutics Inc. CENTRAL INDEX KEY: 0001616212 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1214 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36596 FILM NUMBER: 181045700 BUSINESS ADDRESS: STREET 1: 2488 DUNWIN DRIVE CITY: MISSISSAUGA STATE: A6 ZIP: L5L 1J9 BUSINESS PHONE: (416) 595-0627 MAIL ADDRESS: STREET 1: 2488 DUNWIN DRIVE CITY: MISSISSAUGA STATE: A6 ZIP: L5L 1J9 6-K 1 form6k.htm FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

___________________

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of August, 2018

Commission File Number: 001-36596

___________________

TRILLIUM THERAPEUTICS INC.
(Translation of registrant's name into English)

2488 Dunwin Drive
Mississauga, Ontario L5L 1J9
Canada
(Address of principal executive offices)
___________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [   ]      Form 40-F [X]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)[   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)[   ]

DOCUMENTS FILED AS PART OF THIS FORM 6-K

See the Exhibit Index hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  Trillium Therapeutics Inc.
   
   
Date: August 30, 2018
  By:     /s/ James Parsons                                       
  Name: James Parsons
  Title: Chief Financial Officer

2

EXHIBIT INDEX

Exhibit Description
 
99.1 News Release dated August 30, 2018

EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Trillium Therapeutics Inc.: exhibit 99.1 - Filed by newsfilecorp.com

FOR IMMEDIATE RELEASE NASDAQ: TRIL
  TSX: TRIL

TRILLIUM TO PRESENT AT THE 20th ANNUAL RODMAN & RENSHAW
GLOBAL INVESTMENT CONFERENCE

TORONTO, Aug. 30, 2018 – Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City.

Presenter: Dr. Niclas Stiernholm, Chief Executive Officer
Date: September 5, 2018
Time: 4:15 pm (Eastern Time)
Location: Library (2nd floor)

About Trillium Therapeutics

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “do not eat” signal that cancer cells frequently use to evade the immune system. Trillium also has a proprietary fluorine-based medicinal chemistry platform that is being used to develop novel compounds directed at undisclosed immuno-oncology targets.

For more information visit: www.trilliumtherapeutics.com

Contact:
James Parsons
Chief Financial Officer
Trillium Therapeutics Inc.
416-595-0627 x232
james@trilliumtherapeutics.com
www.trilliumtherapeutics.com

Investor and Media Relations:
Jessica Tieszen
Canale Communications for Trillium Therapeutics
619-849-5385
jessica@canalecomm.com

-2-

GRAPHIC 3 exhibit99-1x1x1.jpg GRAPHIC begin 644 exhibit99-1x1x1.jpg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end